According to the Hemp Business Journal, the CBD market reached an estimated value of $190 million in 2017. Even more staggering than 2017’s numbers is the predicted market value for CBD in 2022; $646 million. In other words, CBD is booming.
In conjunction with rapidly growing markets, CBD has also seen increased research on its medicinal benefits for a wide range of ailments including diabetes, arthritis, insomnia, and nausea. In a relatively recent study, it was found that Cannabidiol (CBD) effectively reduces auto-immune joint damage caused by rheumatoid arthritis and mitigates the incidence of diabetes in mice [1].
Interesting inroads have been made in the study of CBDA; CBD’s raw non-decarboxylated counterpart. Cannabidiolic acid (CBDA) is one of three major compounds found within the cannabis plant alongside THCA (also the raw form of THC) and CBNA [2].
CBDA is a relatively new phenomenon in the field of medical research. Although multiple studies have been conducted to test the effectiveness of CBD, CBDA research lacks the same robust catalogue.
However, a recent study’s results in using dosages of THC combined with CBDA to treat anticipatory nausea in rats has shown great promise. According to the study, CBDA’s anti-nausea properties could be quite effective in the treatment of chemotherapy patients in particular [3].
Even though CBDA research is still in its infant stages, the proposed medicinal benefits in the studies that do exist should be a cause for excitement. One can only hope that CBDA continues to get a piece of the spotlight in medical studies. Perhaps one day we will know much more about its benefits.
- Weiss, et al. “Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.”Autoimmunity. 2005; 32(2): 143 [Times cited = 34, Journal impact factor = 2.917]
- Andre, C. M., Hausman, J. F., and Guerriero, G. “Cannabis sativa: The Plant of the Thousand and One Molecules.” Frontiers in Plant Science. 2016; 7(19): 4-5 [Times cited= 32, Journal impact factor = 4.98]
- Rock, E. M., et al. “Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague- Dawley) models of conditioned gaping.” Psychopharmacology. 2015; 232(24): 1 [Times cited = 6, Journal impact factor = 3.875]
Photo courtesy of healthline.com
